Gamida Cell Ltd. (Nasdaq: GMDA) stock was surging up 55.21% to reach $15.35 in the pre-market session. Over the past 3 months, the company’s stock has gone up 69.06%. With a 12-month market performance over 111.32% higher, GMDA shares are trading 17.88% higher year to date (YTD).
Gamida Cell is a cell therapy company dedicated to the treatment of blood cancers and serious blood diseases. With our cell expansion platform, we’re creating treatments that could potentially rewrite the rules for standards of care in a range of critical medical needs.
What is the latest News?
On February 10, 2021, it was revealed that during the Second Plenary Session of the Transplantation & Cellular Therapy Meetings, Gamida Cell Ltd. (Nasdaq: GMDA) presented results of the Phase 3 clinical study of omidubicel for the first time. Omidubicel is an advanced stem cell therapy under development that can be used in a life-saving process in patients suffering from hematologic malignancies.
A high-risk hematologic malignancy patient was included in the international, multi-center, randomized Phase 3 study of omidubicel to evaluate its safety and efficacy compared to a group of patients receiving a normal umbilical cord blood transplant. In a peer-reviewed conference, this is the first time these data have been presented. The Gamida Cell’s full presentation can be viewed on the website.
Ratings give investors an idea of their stock’s prospects for a given period of time. Investors may use the analyst’s rating and target price to gain insight into what an analyst believes is the fair price for a stock compared to its market value. Gamida Cell Ltd. (GMDA) stock has been targeted between $12.00 and $25.00 by 6 analysts that follow the company. A consensus price objective for shares of the company is $9.89, suggesting that the stock could decline by -53.39% over the period. From current levels at $17.00, the median price target is 41.82% away.